Wang et al.’s studies that aimed to assess the clinical benefits of immune-checkpoint inhibitor (ICI) treatment have estimated that across almost 50,000 patients with different cancer types, POLD1 mutation occurred in 1.37% of cases [10]. Here, POLD1 is linked to cancer.